. 2021 Nov 18;11(12):e2405. doi: 10.1002/brb3.2405

TABLE 1.

Clinical and demographical data by group at follow‐up

		LS‐OCMB– (n = 28)	LS‐OCMB+ (n = 16)	p Value
Age^†		41.71 ± 7.93	32.06 ± 11.00	.002^a
Sex	Male	5 (17.86)	4 (25.00)	.702^b
Sex	Female	23 (82.14)	12 (75.00)	.702^b
Education	Elementary school	9 (32.14)	1 (6.25)	.153^b
	High school	13 (46.43)	10 (62.50)
	College	6 (21.43)	5 (31.25)
Total relapses^††		2.00 (1.00–3.00)	2.00 (2.00–2.00)	.888^c
EDSS		2.00 (1.50–3.00)	1.50 (1.00–2.00)	.105^c
Immunomodulatory therapy^‡	First‐line	19 (67.86)	11 (68.75)	.640^b
Immunomodulatory therapy^‡	Second‐line	5 (17.86)	1 (6.25)	.640^b

Note: Categorical variables are presented by count and percentage. Continuous variables are presented by mean ± standard deviation or median (1st quartile–3rd quartile).

^a t‐test.

^bFisher's exact test.

^cMann–Whitney U test.

^†Age was collected at baseline.

^††Total relapses refer to total relapses since the disease onset, so all relapses before diagnosis were taken into account.

‡8 individuals (4 LS‐OCMB– and 4 LS‐OCMB+) were enrolled in a clinical trial or were not receiving any disease‐modifying treatment at follow‐up. First‐line therapies: interferon‐beta, glatiramer acetate, teriflunomide, dimethyl fumarate. Second‐line therapies: natalizumab, fingolimod, ocrelizumab, cladribine, alemtuzumab.